AGRX - Agile Therapeutics: Stock Hits 52-Week Low And A Near 52-Week High Around Twirla's AdCom
Agile Therapeutics (AGRX) shares were hammered following the company's Q3 earnings press release that revealed the FDA has raised some concerns regarding Twirla's efficacy and safety. In addition, the FDA is not currently in favor of Agile's planned limitations for use labeling for the company's contraceptive patch, Twirla. This announcement was publicized only two days ahead of Twirla's FDA Advisory Committee "AdCom" on October 30th. This information didn't inject any confidence the AdCom committee was going to vote in support of an FDA approval, or that the FDA will approve. Admittedly, I wasn't